Clik here to view.
#ASRS24: Roche touts Phase 3 Susvimo data in diabetes-related ophthalmic...
Roche has unveiled new two-year data from late-stage studies of its ocular implant Susvimo in patients with diabetic eye conditions, as the Swiss pharma works to relaunch the product in a separate...
View ArticleClik here to view.
GoodRx launches discount for Boehringer Ingelheim's Humira biosimilar
Boehringer Ingelheim has partnered with GoodRx to offer the drugmaker’s Humira biosimilar, adalimumab-adbm, in another move by manufacturers to try and wedge themselves into a market still dominated by...
View ArticleClik here to view.
Phathom wins label expansion on heartburn drug to include non-erosive patients
Phathom Pharmaceuticals is digesting news of an expanded label for its heartburn drug Voquezna. The FDA on Wednesday afternoon approved the drug for the relief of heartburn associated with non-erosive...
View ArticleSanofi seeks deeper roots in India with €400M hub expansion
India is soon to become host to Sanofi’s largest global capacity center as the French pharma plans to spend €400 million ($437 million) and more than double its workforce in Hyderabad. The company is...
View ArticleJ&J ditches epilepsy development with Addex, blindsiding 20-year neuroscience...
Johnson & Johnson has discontinued investment in an epilepsy program out of 20-year partner Addex Therapeutics a few months after the Geneva-based biotech’s drug flunked a mid-stage test. A J&J...
View ArticleParker Institute for Cancer Immunotherapy invests another $125M into research
The Parker Institute for Cancer Immunotherapy, a research network established by tech entrepreneur Sean Parker, announced a new $125 million investment. The latest investment comes from Parker and his...
View ArticleCatalent finishes German expansion; Grünenthal invests in Latin America
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Catalent completed its $25 million expansion at a facility in...
View ArticleBoehringer plans to again increase R&D spending; Valneva, Pfizer to advance...
Plus, news about OPKO, HealthCare Royalty, Inventiva, Exscientia and GT Apeiron: Boehringer Ingelheim ups its R&D budget: Back in April, the company said it would invest €36 billion ($39 billion)...
View ArticleNovartis CEO: Trying to crack obesity market with another first-gen agent is...
Novartis doesn’t want to play the me-too game in obesity. On Thursday, CEO Vas Narasimhan said that trying to compete in the multibillion-dollar obesity market with an injectable or oral GLP-1 or GIP...
View ArticleAveo Oncology’s Fotivda combo fails in Phase 3 kidney cancer test
Adding an immune checkpoint inhibitor did not improve the performance of Aveo Oncology’s Fotivda in a late-phase study in certain patients with renal cell carcinoma, nipping the company’s hopes for a...
View ArticleQ&A: How argenx’s CEO plans to create a sequel to Vyvgart (and beat the IRA)
Tim Van Hauwermeiren is one of Europe’s most successful biotech entrepreneurs, having turned a €1 million investment crisis into a drug company worth more than $28 billion today. The Dutch company’s...
View ArticleArdelyx sues Medicare over attempt to change coverage for dialysis drug
Ardelyx and two kidney patient advocacy groups are suing the US government over plans to change how certain drugs used by dialysis patients are paid for, shifting them out of Medicare’s Part D program...
View ArticleClik here to view.
Artiva's IPO raises $167M to fund company's autoimmune and cancer cell therapies
Cell therapy startup Artiva Biotherapeutics will go public on Friday morning in the 11th biotech IPO this year. Its Wall Street debut adds to the industry’s modest rebuilding in 2024 following a dismal...
View ArticleGRO Biosciences raises $60M for protein therapies from genomically recoded...
A biotech startup trying to expand the limited palette that nature uses to make proteins has raised funds to test its creations in humans for the first time. The company, called GRO Biosciences, is...
View ArticleClik here to view.
Nadir Mahmood returns to Nkarta a year after leaving; BeiGene picks longtime...
Nadir Mahmood For new Nkarta president Nadir Mahmood, home is where the heart is. The five-year veteran of the NK cell therapy biotech is returning after a brief stint as CEO at Rezo Therapeutics....
View ArticleCorrected: Lilly upped its offer for Morphic by $11 per share, documents show
Industry insiders love to say biotechs are bought, not sold. That appears to be the case with autoimmune drug developer Morphic Therapeutic, which is trying to create a next-generation, oral medicine...
View Article#ASRS24: Roivant recently sold one spinout for billions. Is Priovant next?
When Roivant announced positive Phase 2 data of a key inflammatory drug back in April, the CEO of Priovant — the subsidiary in charge of development — started to get more calls. The drug, brepocitinib,...
View ArticleOrbiMed forms biotech with assets from China-based Keymed, enlists former...
OrbiMed, a longtime biotech funder, created a startup with two bispecific antibodies licensed from a drugmaker in China and put a former Biohaven executive at the helm. Belenos Biosciences, a New...
View ArticleRona Therapeutics raises $35M; Actuate now plans for $22M IPO
Shanghai-based RNA company raises $35 million: Rona Therapeutics’ Series A+ round was led by LongRiver Investments. Investors include Lilly Asia Ventures, among others. The company is developing RNA...
View ArticleEuropean Commission president’s second-term pledge: simpler regulations,...
Ursula von der Leyen won a second term as president of the European Commission on Thursday, with 401 votes in favor from a total of 719 in the European Parliament. After her win, von der Leyen...
View Article